Lorlatinib Induced Non-cardiogenic Pulmonary Edema: A Case Report

被引：0

作者：

Matsuoka, Suzuka ^{[1
]}

Watanabe, Hiromi ^{[1
]}

Inoue, Tomoyoshi ^{[1
]}

Takigawa, Yuki ^{[1
]}

Kudo, Kenichiro ^{[1
]}

Sato, Akiko ^{[1
]}

Sato, Ken ^{[1
]}

Fujiwara, Keiichi ^{[1
]}

Shibayama, Takuo ^{[1
]}

机构：

[1] NHO Okayama Med Ctr, Dept Resp Med, Okayama, Japan

来源：

INTERNAL MEDICINE | 2025年

关键词：

lorlatinib; ALK-positive lung adenocarcinoma; non-cardiogenic pulmonary edema; EGFR;

D O I：

10.2169/internalmedicine.5156-24

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

A 71-year-old woman was diagnosed with anaplastic lymphoma kinase (ALK)-positive metastatic lung adenocarcinoma staged as cT1cN3M1c (8th edition). Treatment with lorlatinib (100 mg) was initiated on a daily basis. Three weeks after the first dose, the patient was hospitalized because of lorlatinib-induced noncardiogenic pulmonary edema. The patient's condition improved with diuretic therapy, and lorlatinib was rechallenged at a reduced dose. Follow-up computed tomography revealed a partial response. This is a rare case of non-cardiogenic pulmonary edema as an adverse effect of lorlatinib.

引用

页数：4

共 50 条

[21] Magnetic resonance imaging contrast agent related pulmonary edema: a case report
Demirhan, A.
Tekelioglu, U. Yasar
Akkaya, A.
Dagistan, E.
Ayhan, S. Suzi
Ozturk, S.
Yildiz, I.
Kocoglu, H.
EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2012, 16 : 110 - 112
[22] Lorlatinib experience in a patient with ALK plus non-small cell lung cancer on hemodialysis: A case report
Gurbuz, Ali Fuat
Eryilmaz, Melek Karakurt
Yildiz, Oguzhan
Kaya, Bahattin Engin
Araz, Murat
Artac, Mehmet
JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2025, 31 (01) : 160 - 163
[23] Lorlatinib in the treatment of a rare pulmonary mucoepidermoid carcinoma with EML4-ALK fusion: a case report and literature review
Xu, Zijun
Cong, Xiaofeng
Liu, Ziling
FRONTIERS IN ONCOLOGY, 2024, 14
[24] Lorlatinib-Induced Pulmonary Embolism in a Patient With an ALK-Positive NSCLC
Toyozawa, Ryo
Haratake, Naoki
Toyokawa, Gouji
Matsubara, Taichi
Takamori, Shinkichi
Miura, Naoko
Yamaguchi, Masafumi
Takenoyama, Mitsuhiro
Seto, Takashi
JTO CLINICAL AND RESEARCH REPORTS, 2020, 1 (02):
[25] An Internist's Approach to a Case of Negative Pressure Pulmonary Edema: A Rare Cause of Noncardiogenic Pulmonary Edema
Cerna-Viacava, Renato
Almajed, Mohamed Ramzi
Corrales, Julio Pinto
CUREUS JOURNAL OF MEDICAL SCIENCE, 2023, 15 (05)
[26] Long term efficacy and safety of Lorlatinib in ALK-positive non-small cell lung cancer: A case report
Qian, Jialin
Chu, Tianqing
CURRENT PROBLEMS IN CANCER: CASE REPORTS, 2025, 17
[27] Case report: Dissolving carotid plaque associated to Lorlatinib-related dyslipidemia
Mayer-Suess, Lukas
Knoflach, Michael
Pircher, Andreas
Kiechl, Stefan
Schmidauer, Christoph
Hametner, Eva
FRONTIERS IN ONCOLOGY, 2024, 14
[28] Successful Treatment with Lorlatinib after the Development of Alectinib-Induced Liver Damage in ALK-Positive Non-Small-Cell Lung Cancer: A Case Report
Makimoto, Go
Kawakado, Keita
Nakanishi, Masamoto
Tamura, Tomoki
Kuyama, Shoichi
CASE REPORTS IN ONCOLOGY, 2021, 14 (01): : 197 - 201
[29] Successful Lorlatinib Rechallenge After Severe Drug-Induced Psychosis in ALK-Positive Metastatic NSCLC: A Case Report
John, Alexius
Vick, Joanna
Sarker, Sarah
Middleton, Elizabeth
Cartwright, Elizabeth
Manickavasagar, Thubeena
McMahon, David
Tokaca, Nadza
Popat, Sanjay
JTO CLINICAL AND RESEARCH REPORTS, 2024, 5 (07):
[30] Epithelioid inflammatory myofibroblastic sarcoma with exceptionally long response to lorlatinib-a case report
Becht, Rafal
Kielbowski, Kajetan
Zychowska, Justyna
Poncyljusz, Wojciech
Lanocha, Aleksandra
Kozak, Katarzyna
Gabrysz-Trybek, Ewa
Domagala, Pawel
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2024, 16

← 1 2 3 4 5 →